 |
市场调查报告书
商品编码
1629722
乙酰胺酚静脉注射市场：按类型、按应用、按最终用户、按地区Paracetamol IV Market, By Type, By Application, By End User, By Geography |
||||||
预计2024年全球乙酰胺酚注射市场规模为8.381亿美元，预计2031年将达到10.541亿美元，2024年至2031年复合年增长率为3.3%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 8.381 亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024-2031 |
| 预测 2024-2031 年复合年增长率： | 3.30% | 2031年价值预测 | 10.541 亿美元 |
乙酰胺酚，也称为对乙酰胺酚，是最常用的非处方止痛和退烧药之一。主要用于治疗头痛、肌肉痛、背痛、牙痛、感冒、发烧。静脉注射时，对乙酰胺酚比口服给药时更快吸收到血液中。因此，静脉注射适合吞嚥锭剂有困难或经历剧烈疼痛的患者。癌症等慢性疾病的增加可能会增加静脉注射乙酰胺酚溶液的需求，而癌症等慢性疾病的疼痛管理很重要。此外，新配方的快速核准和对疼痛管理日益增长的兴趣可能会在预测期内为全球乙酰胺酚静脉注射市场参与者提供利润丰厚的机会。
市场动态
全球静脉注射乙酰胺酚市场的成长主要是由全球老年人口不断增加所推动的，老年人口更容易患慢性疾病和需要疼痛管理的损伤。根据世界卫生组织公布的资料，到2024年10月1日，65岁及以上的人口预计将从2010年的估计5.24亿增加到2050年的约15亿。患有骨质疏鬆症和关节炎等痛苦疾病的老年人口不断增加，增加了对强效止痛药的需求。然而，市场成长可能会受到某些挑战的阻碍，例如替代药物的可用性以及长期使用静脉注射乙酰胺酚相关的副作用风险。癌症研究的医学进步导致更有效的治疗方法的发现。这可能会增加对乙酰胺酚等静脉镇痛药的需求，以控制化疗引起的疼痛。此外，製药公司对开发新型製剂的日益关注可能会为静脉注射乙酰胺酚市场开闢新的途径。
本研究的主要特点
本报告对全球乙酰胺酚静脉注射剂市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数，包括全球乙酰胺酚静脉注射市场的主要企业概况。
本研究涵盖的主要企业包括强生公司、Fresenius Kabi AG、Baxter International Inc.、辉瑞公司、B. Braun Melsungen AG、Hikma Pharmaceuticals PLC、Amgen Inc.、Sandoz（诺华子公司）、Teva Pharmaceutical Industries Ltd.。 Mylan NV、Eton Pharmaceuticals, Inc.、Aurobindo Pharma Ltd.、Sun Pharmaceutical Industries Ltd.、Apotex Inc.、Mallinckrodt包括药品。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
乙酰胺酚静脉注射全球市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球乙酰胺酚静脉注射市场的各种策略矩阵，将促进相关人员的决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章 市场动态、法规与趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 机会
- 影响分析
- 主要进展
- 监管场景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
- 产业动态
第四章全球乙酰胺酚静脉注射市场，依类型，2019-2031
- 单一剂量
- 多剂量
第五章全球乙酰胺酚静脉注射市场，依应用分类，2019-2031
- 疼痛管理
- 退烧
第六章 全球乙酰胺酚静脉注射市场，依最终用户划分，2019-2031
- 医院
- 诊所
- 家庭护理设置
- 其他的
第七章全球乙酰胺酚静脉注射市场，按地区，2019-2031
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第八章 竞争格局
- Johnson & Johnson
- Fresenius Kabi AG
- Baxter International Inc.
- Pfizer Inc.
- B. Braun Melsungen AG
- Hikma Pharmaceuticals PLC
- Amgen Inc.
- Sandoz（a Novartis division）
- Teva Pharmaceutical Industries Ltd.
- Mylan NV
- Eton Pharmaceuticals, Inc.
- Aurobindo Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc.
- Mallinckrodt Pharmaceuticals
第九章 分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第10章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Global paracetamol IV market is estimated to be valued at USD 838.1 Mn in 2024 and is expected to reach USD 1,054.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 838.1 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 3.30% | 2031 Value Projection: | US$ 1,054.1 Mn |
Paracetamol, also known as acetaminophen, is among the most commonly used over-the-counter pain reliever and fever reducer. It is primarily used for treating headaches, muscle aches, backaches, toothaches, colds, and fevers. The intravenous route enables faster absorption of paracetamol into the bloodstream compared to the oral route. This makes the intravenous formulation a suitable option for patients who have difficulty in swallowing tablets or are experiencing severe pain. Rising cases of chronic diseases such as cancer, where pain management is crucial, can boost the demand for paracetamol IV solutions. Furthermore, rapid approval of new formulations and growing focus on pain management can present lucrative opportunities for global paracetamol IV market players over the forecast period.
Market Dynamics
Global paracetamol IV market growth is primarily driven by rising geriatric population worldwide who are more susceptible to chronic illnesses and injuries requiring pain management. According to the data published by the WHO, on October 1, 2024, the number of people aged 65 years or older is projected to increase from an estimated 524 million in 2010 to nearly 1.5 billion in 2050. Growing incidence of painful conditions like osteoporosis and arthritis in the elderly population boosts the need for potent intravenous painkillers. However, market growth can be hampered by certain challenges such as availability of alternative drugs and risk of adverse effects associated with prolonged usage of paracetamol IV. Ongoing medical advances in cancer research leads to the discovery of more effective therapies. This can boost demand for intravenous analgesics like paracetamol for managing chemotherapy-induced pain. Moreover, increasing focus of pharmaceutical companies on developing novel drug formulations can open new avenues for the paracetamol IV market.
Key features of the study
This report provides in-depth analysis of the global paracetamol IV market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global paracetamol IV market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Fresenius Kabi AG, Baxter International Inc., Pfizer Inc., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Amgen Inc., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Mylan N.V., Eton Pharmaceuticals, Inc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., and Mallinckrodt Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global paracetamol IV market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global paracetamol IV market
Market Segmentation
- Type Insights (Revenue, USD Mn, 2019 - 2031)
- Single Dose
- Multi-Dose
- Application Insights (Revenue, USD Mn, 2019 - 2031)
- Pain Management
- Fever Reduction
- End User Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals
- Clinics
- Homecare Settings
- Others
- Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Johnson & Johnson
- Fresenius Kabi AG
- Baxter International Inc.
- Pfizer Inc.
- B. Braun Melsungen AG
- Hikma Pharmaceuticals PLC
- Amgen Inc.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Eton Pharmaceuticals, Inc.
- Aurobindo Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc.
- Mallinckrodt Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Paracetamol IV Market, By Type
- Global Paracetamol IV Market, By Application
- Global Paracetamol IV Market, By End User
- Global Paracetamol IV Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Paracetamol IV Market, By Type, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Single Dose
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Multi-Dose
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Global Paracetamol IV Market, By Application, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Fever Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Paracetamol IV Market, By End User, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Paracetamol IV Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2020- 2031, (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- B. Braun Melsungen AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz (a Novartis division)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eton Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mallinckrodt Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
